JP2016512825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512825A5 JP2016512825A5 JP2016501110A JP2016501110A JP2016512825A5 JP 2016512825 A5 JP2016512825 A5 JP 2016512825A5 JP 2016501110 A JP2016501110 A JP 2016501110A JP 2016501110 A JP2016501110 A JP 2016501110A JP 2016512825 A5 JP2016512825 A5 JP 2016512825A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- compound
- sbc
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 22
- -1 hydroxysulfonyloxy Chemical group 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 8
- 201000001320 Atherosclerosis Diseases 0.000 claims 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims 7
- 208000032928 Dyslipidaemia Diseases 0.000 claims 7
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 7
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 7
- 208000029078 coronary artery disease Diseases 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 4
- 125000005138 alkoxysulfonyl group Chemical group 0.000 claims 4
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims 4
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 4
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 4
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 150000003857 carboxamides Chemical class 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000005518 carboxamido group Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- VVYIXKBHQQSREP-ORIPQNMZSA-N (4e)-4-[hydroxy-(3-methyl-4-phenylmethoxyphenyl)methylidene]-1-(3-morpholin-4-ylpropyl)-5-pyridin-4-ylpyrrolidine-2,3-dione Chemical compound CC1=CC(C(\O)=C\2C(C(=O)N(CCCN3CCOCC3)C/2C=2C=CN=CC=2)=O)=CC=C1OCC1=CC=CC=C1 VVYIXKBHQQSREP-ORIPQNMZSA-N 0.000 claims 1
- UURZBASXTXQHLN-UHFFFAOYSA-N 2-(3-chlorophenyl)-4-hydroxy-3-(7-methoxy-1-benzofuran-2-carbonyl)-1-(3-morpholin-4-ylpropyl)-2h-pyrrol-5-one Chemical compound O1C=2C(OC)=CC=CC=2C=C1C(=O)C(C1C=2C=C(Cl)C=CC=2)=C(O)C(=O)N1CCCN1CCOCC1 UURZBASXTXQHLN-UHFFFAOYSA-N 0.000 claims 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 claims 1
- MTSHYYTUXDJHNZ-UHFFFAOYSA-N 4-[[2-[(4-cyclopropyl-5-thiophen-2-yl-1,2,4-triazol-3-yl)sulfanyl]acetyl]amino]-n,n-diethylbenzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1NC(=O)CSC(N1C2CC2)=NN=C1C1=CC=CS1 MTSHYYTUXDJHNZ-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- QZFTVSQWMKGSGR-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C=C(C(=O)C2=C(C(N(C2C=2C=NC=CC=2)CCCN2CCOCC2)=O)O)C=C1)C Chemical compound C(C1=CC=CC=C1)OC1=C(C=C(C(=O)C2=C(C(N(C2C=2C=NC=CC=2)CCCN2CCOCC2)=O)O)C=C1)C QZFTVSQWMKGSGR-UHFFFAOYSA-N 0.000 claims 1
- LRPOVGDWHIMCNX-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C=C(C(=O)C2=C(C(N(C2C=2SC=CC=2)CCCN2CCOCC2)=O)O)C=C1)C Chemical compound C(C1=CC=CC=C1)OC1=C(C=C(C(=O)C2=C(C(N(C2C=2SC=CC=2)CCCN2CCOCC2)=O)O)C=C1)C LRPOVGDWHIMCNX-UHFFFAOYSA-N 0.000 claims 1
- VTPCAPXHOATEKH-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=CC(=C(C(=O)C2=C(C(N(C2C=2C=NC=CC=2)CCCN2CCOCC2)=O)O)C=C1)C Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C(=O)C2=C(C(N(C2C=2C=NC=CC=2)CCCN2CCOCC2)=O)O)C=C1)C VTPCAPXHOATEKH-UHFFFAOYSA-N 0.000 claims 1
- MZRVHLINDADTSP-UHFFFAOYSA-N CN(CCCN1C(C(=C(C1C1=CC(=CC=C1)O)C(C1=CC=C(C=C1)OCC1=CC(=CC=C1)C)=O)O)=O)C Chemical compound CN(CCCN1C(C(=C(C1C1=CC(=CC=C1)O)C(C1=CC=C(C=C1)OCC1=CC(=CC=C1)C)=O)O)=O)C MZRVHLINDADTSP-UHFFFAOYSA-N 0.000 claims 1
- FZDSYMVTJPUUJC-UHFFFAOYSA-N OC=1C(N(C(C=1C(C1=CC=C(C=C1)OCC1=C(C=CC=C1)C)=O)C1=CC(=CC=C1)O)CCCN1C=NC=C1)=O Chemical compound OC=1C(N(C(C=1C(C1=CC=C(C=C1)OCC1=C(C=CC=C1)C)=O)C1=CC(=CC=C1)O)CCCN1C=NC=C1)=O FZDSYMVTJPUUJC-UHFFFAOYSA-N 0.000 claims 1
- IMYDWFQXINAZRH-UHFFFAOYSA-N OC=1C(N(C(C=1C(C1=CC=C(C=C1)OCC1=CC(=CC=C1)C)=O)C1=CC=NC=C1)CCCN1CCOCC1)=O Chemical compound OC=1C(N(C(C=1C(C1=CC=C(C=C1)OCC1=CC(=CC=C1)C)=O)C1=CC=NC=C1)CCCN1CCOCC1)=O IMYDWFQXINAZRH-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 10
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 10
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 9
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000013218 HFD mouse model Methods 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788061P | 2013-03-15 | 2013-03-15 | |
| US61/788,061 | 2013-03-15 | ||
| PCT/US2014/022957 WO2014150326A1 (en) | 2013-03-15 | 2014-03-11 | Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018190991A Division JP6691948B2 (ja) | 2013-03-15 | 2018-10-09 | 抗プロタンパク質転換酵素サブチリシン／ケキシン９型（抗ｐｃｓｋ９）化合物および心血管疾患の治療および／または予防におけるその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512825A JP2016512825A (ja) | 2016-05-09 |
| JP2016512825A5 true JP2016512825A5 (enExample) | 2017-04-13 |
Family
ID=51580740
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501110A Pending JP2016512825A (ja) | 2013-03-15 | 2014-03-11 | 抗プロタンパク質転換酵素サブチリシン／ケキシン９型（抗ｐｃｓｋ９）化合物および心血管疾患の治療および／または予防におけるその使用方法 |
| JP2018190991A Expired - Fee Related JP6691948B2 (ja) | 2013-03-15 | 2018-10-09 | 抗プロタンパク質転換酵素サブチリシン／ケキシン９型（抗ｐｃｓｋ９）化合物および心血管疾患の治療および／または予防におけるその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018190991A Expired - Fee Related JP6691948B2 (ja) | 2013-03-15 | 2018-10-09 | 抗プロタンパク質転換酵素サブチリシン／ケキシン９型（抗ｐｃｓｋ９）化合物および心血管疾患の治療および／または予防におけるその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160256467A1 (enExample) |
| EP (1) | EP2968266B1 (enExample) |
| JP (2) | JP2016512825A (enExample) |
| CN (1) | CN105228616B (enExample) |
| AU (1) | AU2014237312B2 (enExample) |
| BR (1) | BR112015023294A2 (enExample) |
| CA (1) | CA2904660C (enExample) |
| WO (1) | WO2014150326A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016029037A1 (en) | 2014-08-21 | 2016-02-25 | Srx Cardio, Llc | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity |
| US20170290806A1 (en) * | 2014-09-08 | 2017-10-12 | Temple University-Of The Commonwealth System Of Higher Education | PCSK9 Inhibitors and Methods of Use Thereof |
| US10428029B2 (en) * | 2014-09-10 | 2019-10-01 | Epizyme, Inc. | Isoxazole carboxamide compounds |
| GB201504763D0 (en) | 2015-03-20 | 2015-05-06 | Mironid Ltd | Compounds and uses |
| TN2017000483A1 (en) | 2015-05-20 | 2019-04-12 | Amgen Inc | Triazole agonists of the apj receptor. |
| JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用 |
| CN105214087B (zh) | 2015-10-29 | 2017-12-26 | 陈敏 | Pcsk9单克隆抗体在制备治疗炎症免疫性疾病药物中的应用 |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| WO2017222953A1 (en) | 2016-06-21 | 2017-12-28 | Shifa Biomedical Corporation | Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases |
| AU2017281332A1 (en) | 2016-06-24 | 2018-12-20 | F. Hoffmann-La Roche Ag | Compositions and methods for treating cardiovascular disease |
| GB201616439D0 (en) | 2016-09-28 | 2016-11-09 | Mironid Limited | Compounds and uses |
| WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| MA46827A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| TW201823222A (zh) * | 2016-12-23 | 2018-07-01 | 財團法人生物技術開發中心 | 化合物、醫藥組成物及其用途 |
| US11091466B2 (en) | 2017-03-17 | 2021-08-17 | Cardio Therapeutics Pty Ltd | Heterocyclic inhibitors of PCSK9 |
| CN107596373A (zh) * | 2017-09-28 | 2018-01-19 | 韩庆亮 | 一种用于治疗心血管疾病的方法 |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| WO2019169193A1 (en) | 2018-03-01 | 2019-09-06 | Annapurna Bio Inc. | Compounds and compositions for treating conditions associated with apj receptor activity |
| GB201805527D0 (en) | 2018-04-04 | 2018-05-16 | Mironid Ltd | Compounds and their use as pde4 activators |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| JOP20190150A1 (ar) | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
| WO2019246386A1 (en) | 2018-06-21 | 2019-12-26 | Ra Pharmaceuticals Inc. | Cyclic polypeptides for pcsk9 inhibition |
| EP3810177B1 (en) | 2018-06-21 | 2024-12-04 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for pcsk9 inhibition |
| CN112969684B (zh) * | 2018-11-05 | 2023-11-10 | 实发生物医学公司 | 抗前蛋白转化酶枯草杆菌蛋白酶Kexin 9型(抗PCSK9)纳米制剂化合物及使用其的方法 |
| CN119060040A (zh) | 2019-01-18 | 2024-12-03 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
| WO2022251533A1 (en) * | 2021-05-27 | 2022-12-01 | Protego Biopharma, Inc. | Heteroaryl diamide ire1/xbp1s activators |
| TW202423430A (zh) * | 2022-10-14 | 2024-06-16 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮雜環類衍生物抑制劑、其製備方法和應用 |
| EP4626865A1 (en) * | 2022-11-30 | 2025-10-08 | Protego Biopharma, Inc. | Cyclic pyrazole diamide ire1/xbp1s activators |
| WO2025021188A1 (zh) * | 2023-07-27 | 2025-01-30 | 上海拓界生物医药科技有限公司 | 二氨基环戊基取代的杂芳基衍生物及其用途和制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017313A (en) * | 1974-09-30 | 1977-04-12 | E. I. Du Pont De Nemours And Company | Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process |
| DE3021590A1 (de) * | 1980-06-09 | 1981-12-17 | Hoechst Ag, 6000 Frankfurt | 4-halogen-5-(halogenmethyl-phenyl)-oxazol-derivate, ein verfahren zu ihrer herstellung und sie enthaltenden strahlungsempfindliche massen |
| US20030130343A1 (en) * | 2001-08-10 | 2003-07-10 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| RU2004109818A (ru) * | 2001-10-03 | 2005-05-10 | Юсиби, С.А. (Be) | Производные пирролидинона |
| WO2004089416A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| EP2007717A1 (en) * | 2006-04-11 | 2008-12-31 | Actelion Pharmaceuticals Ltd. | Novel sulfonamide compounds |
| US20090275053A1 (en) * | 2008-04-30 | 2009-11-05 | Board Of Regents, The University Of Texas System | Cell-based pcsk9 screening assay |
| GB201205653D0 (en) * | 2012-03-30 | 2012-05-16 | Jaguar Cars | Wade sensing display control system |
-
2014
- 2014-03-11 WO PCT/US2014/022957 patent/WO2014150326A1/en not_active Ceased
- 2014-03-11 EP EP14770138.7A patent/EP2968266B1/en active Active
- 2014-03-11 AU AU2014237312A patent/AU2014237312B2/en not_active Ceased
- 2014-03-11 CA CA2904660A patent/CA2904660C/en active Active
- 2014-03-11 BR BR112015023294A patent/BR112015023294A2/pt not_active IP Right Cessation
- 2014-03-11 CN CN201480016193.8A patent/CN105228616B/zh not_active Expired - Fee Related
- 2014-03-11 JP JP2016501110A patent/JP2016512825A/ja active Pending
-
2016
- 2016-05-12 US US15/152,703 patent/US20160256467A1/en not_active Abandoned
-
2018
- 2018-10-09 JP JP2018190991A patent/JP6691948B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512825A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2006513202A5 (enExample) | ||
| JP2017530999A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| RU2012127760A (ru) | Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний | |
| JP2016512558A5 (enExample) | ||
| UA88938C2 (ru) | Твердые фармацевтические формы для перорального введения, которые содержат ривароксабан, с модифицированным высвобождением | |
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| JP2016506964A5 (ja) | ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド | |
| JP2013543896A5 (enExample) | ||
| KR20200058606A (ko) | 면역-관련 및 염증성 질환의 치료 | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| RU2011105151A (ru) | Азольные соединения | |
| JP2016534124A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2006514611A5 (enExample) | ||
| RU2015121043A (ru) | Производные фенилэтилпиридина в качестве ингибиторов PDE-4 | |
| RU2009111378A (ru) | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5 | |
| JP2020529995A5 (enExample) | ||
| JP2017014224A (ja) | 帯状疱疹関連痛の急性期疼痛の予防又は治療剤 | |
| JP2013506674A5 (enExample) | ||
| TW201912153A (zh) | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 | |
| JP2017119702A (ja) | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 | |
| RU2006134022A (ru) | Производные индазола и содержащие их фармацевтические композиции |